Biotech's Next Big Thing: Merck
Alzheimer drugs with a focus on Merck will be on investors minds in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
